Key facts
- Alchemab Therapeutics’s last known valuation is $138.0M (Sep 2025).
- It has raised $32.1M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($31.9M) in Sep 2025.
- Notable investors include Innovate UK, RA Capital Management, DCVC, SV Health Investors, Camford Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Alchemab Therapeutics
Funding rounds
1 roundsAbout Alchemab Therapeutics
Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. The company's antibodies are found through an unbiased and function-first approach using three complementary processes and technologies, enabling patients to control the power of naturally protective antibodies and get themselves treated.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 60
- Website
- alchemab.com/
- Ownership
- Privately Held (backing)
Alchemab Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alchemab Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alchemab Therapeutics in its N-PORT filings yet. We sweep new filings monthly.